Jazz Hits Teva With Patent Suit Over Narcolepsy Drug

By Carla Baranauckas · August 29, 2024, 3:40 PM EDT

Teva Pharmaceuticals Inc. is infringing a patent for the narcolepsy drug Xywav, Jazz Pharmaceuticals Inc. said in a complaint filed in New Jersey federal court....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

JAZZ PHARMACEUTICALS IRELAND LIMITED v. TEVA PHARMACEUTICALS, INC.

Case Number

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

August 27, 2024

Recent Articles By Carla

October 25, 2024
NJ Ethics Board Faces Contempt Bid In Retaliation Fight
October 18, 2024
Hospital, Medical Practice Ink $12M Deal In Brain Damage Suit
September 20, 2024
3rd Circ. Rejects 'Close' Case For Preemption In Fosamax MDL
August 14, 2024
Doctor Loses Challenge To Nursing Home's Vax Policy
August 05, 2024
Nursing Home Flubs Make Reports Fair Game, NJ Justices Say
July 18, 2024
PharMerica Inks $100M Deal In 13-Year-Old Whistleblower Suit
July 11, 2024
NJ Justices Back Expert Report In Mother's Suit Over Death
July 10, 2024
Ex-CEO Convicted In COVID Test Kit Fraud Case
July 09, 2024
NJ Jury Begins Deliberating COVID Test Kit Fraud Case
July 08, 2024
Jurors Told To Decide Who Is Lying In COVID Test Fraud Case